Skip to main content

Table 3 Dermatological diagnosis before and after 6-week treatment with SkinCera

From: Potential benefits of oral administration of AMORPHOPHALLUS KONJAC glycosylceramides on skin health – a randomized clinical study

 

SkinCera group

Placebo group

Parameter

Number of subjects with symptoms

Before treatment

After 3 weeks

After 6 weeks

Number of subjects with symptoms

Before treatment

After 3 weeks

After 6 weeks

Dryness

8

1.88 ± 0.99

0.5 ± 0.75**

0.63 ± 0.51**

12

1.33 ± 0.49

1.58 ± 0.51

1.67 ± 0.65

Whiteheads/ blackheads

10

1.56 ± 0.72

1.0 ± 0.86

1.11 ± 0.78

11

1.91 ± 0.83

2.46 ± 0.52

2.55 ± 0.69

Hyperpigmentation

21

1.47 ± 0.77

1.05 ± 0.52

1.05 ± 0.40*

11

2.46 ± 0.52

2.36 ± 0.5

2.14 ± 0.69

Redness

10

1.7 ± 0.67

1.2 ± 0.91

0.6 ± 0.84*

5

1.20 ± 0.44

1.8 ± 0.44

LTF

Lesions

11

1.3 ± 0.48

1.1 ± 0.87

0.7 ± 0.82

5

1.4 ± 0.54

1.8 ± 0.45

LTF

Itching

10

1.67 ± 0.5

0.88 ± 0.78

0.67 ± 0.86*

3

1.33 ± 0.57

2.33 ± 0.57

LTF

Oilyness

12

1.46 ± 0.52

0.90 ± 0.83

0.73 ± 0.78*

9

1.11 ± 0.33

1.22 ± 0.44

1.71 ± 0.48*

Roughness

7

1.29 ± 0.48

0.71 ± 0.75

0.57 ± 0.78

11

1.91 ± 0.83

2.27 ± 0.47

2.36 ± 0.81

Overall

26

1.53 ± 0.66

0.95 ± 0.76***

0.79 ± 0.71***

25

1.67 ± 0.74

1.98 ± 0.63*

2.10 ± 0.75**

  1. The values are the mean in each group; analyzed by one-way ANOVA followed by Dunnet’s t test. The data were statistically significant at *p < 0.05, **p < 0.01, ***p < 0.001 within the group. LTF, Lost to follow-up
  2. 0 (no symptoms) - 1 (mild) - 2 (moderate) - 3 (severe)